Harmony Biosciences Holdings
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $37.84
- Today's High:
- $39.24
- Open Price:
- $38.13
- 52W Low:
- $29.81
- 52W High:
- $62.085
- Prev. Close:
- $38.05
- Volume:
- 554956
Company Statistics
- Market Cap.:
- $2.17 billion
- Book Value:
- 8.086
- Revenue TTM:
- $498.86 million
- Operating Margin TTM:
- 29.44%
- Gross Profit TTM:
- $354.37 million
- Profit Margin:
- 40.14%
- Return on Assets TTM:
- 14.51%
- Return on Equity TTM:
- 54.73%
Company Profile
Harmony Biosciences Holdings had its IPO on 2020-08-19 under the ticker symbol HRMY.
The company operates in the Healthcare sector and Biotechnology industry. Harmony Biosciences Holdings has a staff strength of 200 employees.
Stock update
Shares of Harmony Biosciences Holdings opened at $38.13 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $37.84 - $39.24, and closed at $39.03.
This is a +2.58% increase from the previous day's closing price.
A total volume of 554,956 shares were traded at the close of the day’s session.
In the last one week, shares of Harmony Biosciences Holdings have increased by +8.15%.
Harmony Biosciences Holdings's Key Ratios
Harmony Biosciences Holdings has a market cap of $2.17 billion, indicating a price to book ratio of 10.1167 and a price to sales ratio of 8.308.
In the last 12-months Harmony Biosciences Holdings’s revenue was $498.86 million with a gross profit of $354.37 million and an EBITDA of $171.10 million. The EBITDA ratio measures Harmony Biosciences Holdings's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Harmony Biosciences Holdings’s operating margin was 29.44% while its return on assets stood at 14.51% with a return of equity of 54.73%.
In Q2, Harmony Biosciences Holdings’s quarterly earnings growth was a positive 43.6% while revenue growth was a positive 25.4%.
Harmony Biosciences Holdings’s PE and PEG Ratio
- Forward PE
- 25.641
- Trailing PE
- 10.7731
- PEG
Its diluted EPS in the last 12-months stands at $3.35 per share while it has a forward price to earnings multiple of 25.641 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Harmony Biosciences Holdings’s profitability.
Harmony Biosciences Holdings stock is trading at a EV to sales ratio of 8.3914 and a EV to EBITDA ratio of 27.2506. Its price to sales ratio in the trailing 12-months stood at 8.308.
Harmony Biosciences Holdings stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $760.18 million
- Total Liabilities
- $93.05 million
- Operating Cash Flow
- $-7771000.00
- Capital Expenditure
- $205000
- Dividend Payout Ratio
- 0%
Harmony Biosciences Holdings ended 2024 with $760.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $760.18 million while shareholder equity stood at $485.17 million.
Harmony Biosciences Holdings ended 2024 with $0 in deferred long-term liabilities, $93.05 million in other current liabilities, 1000.00 in common stock, $-208345000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $317.42 million and cash and short-term investments were $370.98 million. The company’s total short-term debt was $11,000,000 while long-term debt stood at $180.49 million.
Harmony Biosciences Holdings’s total current assets stands at $455.64 million while long-term investments were $58.65 million and short-term investments were $53.57 million. Its net receivables were $63.81 million compared to accounts payable of $6.56 million and inventory worth $4.85 million.
In 2024, Harmony Biosciences Holdings's operating cash flow was $-7771000.00 while its capital expenditure stood at $205000.
Comparatively, Harmony Biosciences Holdings paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $39.03
- 52-Week High
- $62.085
- 52-Week Low
- $29.81
- Analyst Target Price
- $58.5
Harmony Biosciences Holdings stock is currently trading at $39.03 per share. It touched a 52-week high of $62.085 and a 52-week low of $62.085. Analysts tracking the stock have a 12-month average target price of $58.5.
Its 50-day moving average was $34.47 and 200-day moving average was $40.95 The short ratio stood at 15.37 indicating a short percent outstanding of 0%.
Around 1938.6% of the company’s stock are held by insiders while 9063.1% are held by institutions.
Frequently Asked Questions About Harmony Biosciences Holdings
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.